Session Details

Moderator

Reshma L Mahtani, Baptist Health Wertheim Cancer Institute, Miami, FL

Moderator

Joyce O'Shaughnessy

Presentation numberRF7-1

Efficacy and Safety of a 6-Month Pre‑mixed Depot formulation, Leuprorelin Mesylate Injection (6M) with Tamoxifen in Premenopausal HR+ Breast Cancer: A Phase III, Randomized, Open-Label, Non-Inferiority Study in China

Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China

Presentation numberRF7-2

I-SPY 2 Endocrine Optimization Pilot (EOP): elagolix vs GnRH agonist as ovarian function suppression (OFS) in premenopausal patients receiving neoadjuvant (Z)-endoxifen for estrogen receptor positive (ER+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC)

Annabelle Duflock, University of California, San Francisco, San Francisco, CA

Presentation numberRF7-3

A randomised non-comparative phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES); EORTC-1745-ETF-BCG

Hans Wildiers, university hospitals leuven, leuven, Belgium

Presentation numberRF7-4

Afuresertib and fulvestrant for PIK3CA/AKT1/PTEN-altered, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III part of LAE205INT3101 trial

Pin Zhang, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Presentation numberRF7-5

Updated Efficacy Results From LEONARDA-2: A Phase III, Randomized, Placebo-Controlled Trial of Lerociclib Plus Letrozole as First-Line Therapy for HR+/HER2- Advanced Breast Cancer

Xichun Hu, Fudan University Cancer Center, Shanghai, China